Our investigation of blood‐based datasets GSE30174 and GSE53922 from PCa patients revealed that 4 genes from our ECMG signature, including FBP1, ERBB3, CACNA1D and APEX1, were not only significantly altered in localised PCa patients post‐EBRT but also held prognostic value in stratifying CRPC patients into high‐ and low‐risk categories for overall survival. This evidence concerns the gene ERBB3 and posterior cortical atrophy.